Eli Lilly is announcing 70-percent price cuts on its most commonly prescribed insulin. The move comes as Eli Lilly and other insulin makers face ongoing criticism about high prices driving some diabetics to ration the life-saving drug. Starting in October, the price of a Humalog 100 units vial will be slashed to 66-dollars, down from two-hundred-seventy-four. And Lilly, based in Indianapolis, says starting in May, it’ll cap out-of-pocket insulin costs at 35-dollars a month for people with insurance. Eli Lilly and two foreign pharmaceutical companies with New Jersey headquarters, Novo Nordisk and Sanofi, control the insulin market.
***Courtesy of Total Traffic News***
